RAMM Pharma Corp.
RAMM
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 6.81% | -48.13% | -37.75% | 77.05% | 12.47% |
| Total Depreciation and Amortization | -14.48% | -28.09% | -6.84% | -31.46% | -2.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.47% | 7.22% | 323.42% | -83.67% | -29.24% |
| Change in Net Operating Assets | -216.44% | 148.09% | -211.11% | -118.03% | 138.04% |
| Cash from Operations | -71.37% | 15.55% | -5.86% | 33.38% | 26.72% |
| Capital Expenditure | -- | 95.45% | -88.24% | -7,620.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 262.68% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -124.14% | 1.90% | 200.72% | -79.80% | 1,557.14% |
| Cash from Investing | -163.36% | 46.35% | -23.33% | 112.29% | 266.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -23.88% | 1.70% | 35.06% | 59.49% | -919.57% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -20.70% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 31.71% | 21.74% | -- | 5,416.67% | -12,400.00% |
| Cash from Financing | 63.95% | 7.14% | 60.47% | 92.29% | 82.69% |
| Foreign Exchange rate Adjustments | 132.43% | 234.04% | -869.23% | -30.65% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -47.96% | 17.79% | -0.72% | 59.86% | 58.25% |
